[Federal Register Volume 80, Number 120 (Tuesday, June 23, 2015)]
[Notices]
[Pages 35974-35975]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-15331]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: Midas 
Pharmaceuticals, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic class, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.34(a) on or before July 23, 2015. Such persons may also file a 
written request for a hearing on the application pursuant to 21 CFR 
1301.43 on or before July 23, 2015.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/ODXL, 
8701 Morrissette Drive, Springfield, Virginia 22152. Request for 
hearings should be sent to: Drug Enforcement Administration, Attention: 
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301,

[[Page 35975]]

incident to the registration of manufacturers, distributors, 
dispensers, importers, and exporters of controlled substances (other 
than final orders in connection with suspension, denial, or revocation 
of registration) has been redelegated to the Deputy Assistant 
Administrator of the DEA Office of Diversion Control (``Deputy 
Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.34(a), this is notice that on 
January 12, 2015, Midas Pharmaceuticals, Inc., 300 Interpace Parkway, 
Suite 420, Parsippany, New Jersey 07054-1100 applied to be registered 
as an importer of remifentanil (9739), a basic class of controlled 
substance listed in schedule II.
    The company plans to import the listed controlled substance in 
order to bulk manufacture controlled substance in Active Pharmaceutical 
Ingredient (API) form. The company distributes the manufactured APIs in 
bulk to its customers.

    Dated: June 12, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-15331 Filed 6-22-15; 8:45 am]
 BILLING CODE 4410-09-P